This umbrella review aims to summarize and evaluate the evidence from current systematic reviews/meta-analyses (SRs/MAs) on the effectiveness of stem cell therapy for diabetic foot (DF).
Approach:
We conducted a comprehensive search in four databases for SRs/MAs that included randomized controlled trials (RCTs) on stem cell therapy for DF. Two separate researchers independently evaluated the methodological quality and evidence quality of the SRs/MAs that were included in the study. We conducted a quantitative synthesis of all RCTs included in the SRs/MAs to obtain objective and updated conclusions. Egger's test and sensitivity analysis are used to examine the reliability of the results.
Results:
This umbrella review includes eight SRs/MAs, and their methodological quality and evidence quality were all deemed unsatisfactory. Out of the 8 SRs/MAs, 26 RCTs were included, with a total corrected covered area of 21.4%, indicating a high degree of overlap. The test of super-significance did not yield any significant results. Our updated meta-analysis suggests that DF patients can benefit from stem cell therapy, as indicated by effectiveness in measures, including healing rate, amputation rate, ankle-brachial index, transcutaneous oxygen pressure, ulcer size reduction, complete healing time, pain-free walking distance, rest pain score, and new angiogenesis rate.
Innovation:
This study conducted a comprehensive evaluation and reanalysis of the current evidence regarding the effectiveness and safety of stem cell therapy for DF, which is the first of its kind.
Conclusion:
Based on the existing evidence, stem cell therapy is effective and safe for patients with DF.
Get full access to this article
View all access options for this article.
References
1.
CrausS, MulaA, CoppiniDV. The foot in diabetes—A reminder of an ever-present risk. Clin Med (Lond), 2023; 23(3):228–233; doi: 10.7861/clinmed2022-0489
2.
BoultonAJ, VileikyteL, Ragnarson-TennvallG, et al.The global burden of diabetic foot disease. Lancet, 2005; 366(9498):1719–1724; doi: 10.1016/S0140-6736(05)67698-2
3.
BandykDF. The diabetic foot: Pathophysiology, evaluation, and treatment. Semin Vasc Surg, 2018; 31(2–4):43–48; doi: 10.1053/j.semvascsurg.2019.02.001
4.
FuXL, DingH, MiaoWW, et al.Global recurrence rates in diabetic foot ulcers: A systematic review and meta-analysis. Diabetes Metab Res Rev, 2019; 35(6):e3160; doi: 10.1002/dmrr.3160
5.
Gallego-SellesA, Martin-RinconM, Martinez-CantonM, et al.Regulation of Nrf2/Keap1 signalling in human skeletal muscle during exercise to exhaustion in normoxia, severe acute hypoxia and post-exercise ischaemia: Influence of metabolite accumulation and oxygenation. Redox Biol, 2020; 36:101627; doi: 10.1016/j.redox.2020.101627
6.
ChenL, ZhengB, XuY, et al.Nano hydrogel-based oxygen-releasing stem cell transplantation system for treating diabetic foot. J Nanobiotechnol, 2023; 21(1):202; doi: 10.1186/s12951-023-01925-z
7.
BlumbergSN, BergerA, HwangL, et al.The role of stem cells in the treatment of diabetic foot ulcers. Diabetes Res Clin Pract, 2012; 96(1):1–9; doi: 10.1016/j.diabres.2011.10.032
8.
ChenP, CarvilleK, SwansonT, et al.Australian guideline on wound healing interventions to enhance healing of foot ulcers: Part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. J Foot Ankle Res, 2022; 15(1):40; doi: 10.1186/s13047-022-00544-5
9.
KrasilnikovaOA, BaranovskiiDS, LyundupAV, et al.Stem and somatic cell monotherapy for the treatment of diabetic foot ulcers: Review of clinical studies and mechanisms of action. Stem Cell Rev Rep, 2022; 18(6):1974–1985; doi: 10.1007/s12015-022-10379-z
10.
EleftheriadouI, SamakidouG, TentolourisA, et al.Nonpharmacological Management of Diabetic Foot Ulcers: An Update. Int J Low Extrem Wounds, 2021; 20(3):188–197; doi: 10.1177/1534734620963561
11.
DinhT, TecilazichF, KafanasA, et al.Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes, 2012; 61(11):2937–2947; doi: 10.2337/db12-0227
12.
SiddawayAP, WoodAM, HedgesLV. How to do a systematic review: A best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses. Annu Rev Psychol, 2019; 70:747–770; doi: 10.1146/annurev-psych-010418-102803
13.
YaoL, SunR, ChenYL, et al.The quality of evidence in Chinese meta-analyses needs to be improved. J Clin Epidemiol, 2016; 74:73–79; doi: 10.1016/j.jclinepi.2016.01.003
14.
GatesM, GatesA, PieperD, et al.Reporting guideline for overviews of reviews of healthcare interventions: Development of the PRIOR statement. BMJ, 2022; 378:e070849; doi: 10.1136/bmj-2022-070849
15.
LiR, DaiG, GuanH, et al.Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: An umbrella review of systematic reviews and meta-analyses. Front Cardiovasc Med, 2023; 10:1143658; doi: 10.3389/fcvm.2023.1143658
16.
PopromN, WilasrusmeeC, AttiaJ, et al.Comparison of postoperative complications between open and laparoscopic appendectomy: An umbrella review of systematic reviews and meta-analyses. J Trauma Acute Care Surg, 2020; 89(4):813–820; doi: 10.1097/TA.0000000000002878
17.
SheaBJ, ReevesBC, WellsG, et al.AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017; 358:j4008; doi: 10.1136/bmj.j4008
18.
PollockA, FarmerSE, BradyMC, et al.An algorithm was developed to assign GRADE levels of evidence to comparisons within systematic reviews. J Clin Epidemiol, 2016; 70:106–110; doi: 10.1016/j.jclinepi.2015.08.013
19.
HennessyEA, JohnsonBT. Examining overlap of included studies in meta-reviews: Guidance for using the corrected covered area index. Res Synth Methods, 2020; 11(1):134–145; doi: 10.1002/jrsm.1390
20.
IoannidisJP, TrikalinosTA. An exploratory test for an excess of significant findings. Clin Trials, 2007; 4(3):245–253; doi: 10.1177/1740774507079441
21.
GuoJ, DardikA, FangK, et al.Meta-analysis on the treatment of diabetic foot ulcers with autologous stem cells. Stem Cell Res Ther, 2017; 8(1):228; doi: 10.1186/s13287-017-0683-2
22.
DaiJ, JiangC, ChenH, et al.Treatment of diabetic foot with autologous stem cells: A meta-analysis of randomized studies. Stem Cells Int, 2020; 2020:6748530; doi: 10.1155/2020/6748530
23.
JinL, WangX, QiaoZ, et al.The safety and efficacy of mesenchymal stem cell therapy in diabetic lower extremity vascular disease: A meta-analysis and systematic review. Cytotherapy, 2022; 24(3):225–234; doi: 10.1016/j.jcyt.2021.08.001
24.
HuangL, HuangX, WangZ, et al.Stem cell treatment for diabetic foot ulcers: A meta-analysis of randomized clinical trials. Adv Skin Wound Care, 2023; 36(5):1; doi: 10.1097/01.ASW.0000924452.07795.31
25.
ElsharkawiM, GhoneimB, O'SullivanM, et al.Role of adipose derived stem cells in patients with diabetic foot ulcers: Systematic review and meta-analysis of randomised controlled trials. Int J Low Extrem Wounds, 2023; 2023:15347346231174554; doi: 10.1177/15347346231174554
26.
ShuX, ShuS, TangS, et al.Efficiency of stem cell based therapy in the treatment of diabetic foot ulcer: A meta-analysis. Endocr J, 2018; 65(4):403–413; doi: 10.1507/endocrj.EJ17-0424
27.
ZhangY, DengH, TangZ. Efficacy of cellular therapy for diabetic foot ulcer: A meta-analysis of randomized controlled clinical trials. Cell Transplant, 2017; 26(12):1931–1939; doi: 10.1177/0963689717738013
28.
SunY, ZhaoJ, ZhangL, et al.Effectiveness and safety of stem cell therapy for diabetic foot: A meta-analysis update. Stem Cell Res Ther, 2022; 13(1):416; doi: 10.1186/s13287-022-03110-9
29.
AlbehairyA, KyrillosF, GawishH, et al.Autologous mononuclear versus mesenchymal stem cells in healing of recalcitrant neuropathic diabetic foot ulcers. Diabetologia, 2018; 61:S7.
30.
OzturkA, KucukardaliY, TangiF, et al.Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. J Diabetes Complications, 2012; 26(1):29–33; doi: 10.1016/j.jdiacomp.2011.11.007
31.
ChenB, LuD, LiangZ, et al.Autologous bone marrow mesenchymal stem cells expanded in vitro and transplanted to treat diabetes foot. China Tissue Eng Res Clin Rehabil, 2009; 13(32):6227–6230.
32.
LuD, JiangY, LiangZ, et al.Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia. J Med Coll PLA, 2008; 3(2):106–115.
33.
LuD, ChenB, LiangZ, et al.Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract, 2011; 92(1):26–36; doi: 10.1016/j.diabres.2010.12.010
QinHL, ZhuXH, ZhangB, et al.Clinical evaluation of human umbilical cord mesenchymal stem cell transplantation after angioplasty for diabetic foot. Exp Clin Endocrinol Diabetes, 2016; 124(8):497–503; doi: 10.1055/s-0042-103684
36.
YouHJ, HanSK, LeeJW, et al.Treatment of diabetic foot ulcers using cultured allogeneic keratinocytes—A pilot study. Wound Repair Regen, 2012; 20(4):491–499; doi: 10.1111/j.1524-475X.2012.00809.x
37.
ParkKH, HanSH, HongJP, et al.Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial. Diabetes Res Clin Pract, 2018; 142:335–344; doi: 10.1016/j.diabres.2018.06.002
38.
MoonKC, SuhHS, KimKB, et al.Potential of allogeneic adipose-derived stem cell-hydrogel complex for treating diabetic foot ulcers. Diabetes, 2019; 68(4):837–846; doi: 10.2337/db18-0699
39.
MohammadzadehL, SamedanifardSH, KeshavarziA, et al.Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia. Exp Clin Endocrinol Diabetes, 2013; 121(1):48–53; doi: 10.1055/s-0032-1311646
40.
LaveryLA, FulmerJ, ShebetkaKA, et al.The efficacy and safety of Grafix(®) for the treatment of chronic diabetic foot ulcers: Results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J, 2014; 11(5):554–560; doi: 10.1111/iwj.12329
41.
DubskyM, JirkovskaA, BemR, et al.Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes Metab Res Rev, 2013; 29(5):369–376; doi: 10.1002/dmrr.2399
42.
DubskýM, JirkovskáA, BemR, et al.Comparison of the effect of stem cell therapy and percutaneous transluminal angioplasty on diabetic foot disease in patients with critical limb ischemia. Cytotherapy, 2014; 16(12):1733–1738; doi: 10.1016/j.jcyt.2014.08.010
43.
DashNR, DashSN, RoutrayP, et al.Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res, 2009; 12(5):359–366; doi: 10.1089/rej.2009.0872
44.
SmithOJ, LeighR, KanapathyM, et al.Fat grafting and platelet-rich plasma for the treatment of diabetic foot ulcers: A feasibility-randomised controlled trial. Int Wound J, 2020; 17(6):1578–1594; doi: 10.1111/iwj.13433
45.
SuiP, SongL, LuY, et al.Effect and potential mechanism of local injection of umbilical cord mesenchymal stem cells in the treatment of diabetes foot. Western Med, 2020; 32(11):1664–1668.
46.
HuangP, LiS, HanM, et al.Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care, 2005; 28(9):2155–2160; doi: 10.2337/diacare.28.9.2155
47.
JainP, PerakathB, JesudasonMR, et al.The effect of autologous bone marrow-derived cells on healing chronic lower extremity wounds: Results of a randomized controlled study. Ostomy Wound Manage, 2011; 57(7):38–44.
48.
LonardiR, LeoneN, GennaiS, et al.Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: A randomized controlled single-center clinical trial (MiFrAADiF). Stem Cell Res Ther, 2019; 10(1):223; doi: 10.1186/s13287-019-1328-4
49.
KiranaS, StratmannB, PranteC, et al.Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients. Int J Clin Pract, 2012; 66(4):384–393; doi: 10.1111/j.1742-1241.2011.02886.x
50.
HanSK, KimHR, KimWK. The treatment of diabetic foot ulcers with uncultured, processed lipoaspirate cells: A pilot study. Wound Repair Regen, 2010; 18(4):342–348; doi: 10.1111/j.1524-475X.2010.00593.x
51.
LiX, ZhuL, SongG, et al.Umbilical cord mesenchymal stem cell transplantation in the treatment of lower limb angiopathy in diabetes. China Tissue Eng Res, 2014; 18(23):3670–3675.
52.
ZhangX, LianW, LouW, et al.Transcatheter arterial infusion of autologous CD133(+) cells for diabetic peripheral artery disease. Stem Cells Int, 2016; 2016:6925357; doi: 10.1155/2016/6925357
53.
HeY. Clinical study of umbilical cord mesenchymal stem cells in the treatment of type 2 diabetes skin ulcer. Chin J Coal Indust Med, 2014; 17(04):532–534.
54.
ZhaoY, ZhuZ, LiA, et al.Application of autologous adipose stem cells in the treatment of diabetes foot wounds. J Clin Surg, 2018; 26(01):63–66.
55.
StewartL, MoherD, ShekelleP. Why prospective registration of systematic reviews makes sense. Syst Rev, 2012; 1:7; doi: 10.1186/2046-4053-1-7
56.
BougioukasKI, VounzoulakiE, MantsiouCD, et al.Methods for depicting overlap in overviews of systematic reviews: An introduction to static tabular and graphical displays. J Clin Epidemiol, 2021; 132:34–45; doi: 10.1016/j.jclinepi.2020.12.004
57.
BahmadHF, ElajamiMK, DaoukR, et al.Stem cells: In sickness and in health. Curr Stem Cell Res Ther, 2021; 16(3):262–276; doi: 10.2174/1574888X15999200831160710
58.
MahjoorM, AfkhamiH, NajafiM, et al.The role of microRNA-30c in targeting interleukin 6, as an inflammatory cytokine, in the mesenchymal stem cell: A therapeutic approach in colorectal cancer. J Cancer Res Clin Oncol, 2023; 149(7):3149–3160; doi: 10.1007/s00432-022-04123-w
59.
HoulindK. Surgical revascularization and reconstruction procedures in diabetic foot ulceration. Diabetes Metab Res Rev, 2020; 36Suppl 1:e3256; doi: 10.1002/dmrr.3256
60.
ShiR, LianW, JinY, et al.Role and effect of vein-transplanted human umbilical cord mesenchymal stem cells in the repair of diabetic foot ulcers in rats. Acta Biochim Biophys Sin (Shanghai), 2020; 52(6):620–630; doi: 10.1093/abbs/gmaa039
61.
ShiR, JinY, CaoC, et al.Localization of human adipose-derived stem cells and their effect in repair of diabetic foot ulcers in rats. Stem Cell Res Ther, 2016; 7(1):155; doi: 10.1186/s13287-016-0412-2
62.
Arango-RodríguezML, Solarte-DavidVA, Becerra-BayonaSM, et al.Role of mesenchymal stromal cells derivatives in diabetic foot ulcers: A controlled randomized phase 1/2 clinical trial. Cytotherapy, 2022; 24(10):1035–1048; doi: 10.1016/j.jcyt.2022.04.002
GentileP, SterodimasA, PizzicannellaJ, et al.Systematic review: Allogenic use of stromal vascular fraction (SVF) and decellularized extracellular matrices (ECM) as advanced therapy medicinal products (ATMP) in tissue regeneration. Int J Mol Sci, 2020; 21(14):4982; doi: 10.3390/ijms21144982
65.
SchaperNC, van NettenJJ, ApelqvistJ, et al.Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev, 2020; 36Suppl 1:e3266; doi: 10.1002/dmrr.3266
HassanWU, GreiserU, WangW. Role of adipose-derived stem cells in wound healing. Wound Repair Regen, 2014; 22(3):313–325; doi: 10.1111/wrr.12173
68.
KanjiS, DasH. Advances of stem cell therapeutics in cutaneous wound healing and regeneration. Mediat Inflamm, 2017; 2017:5217967; doi: 10.1155/2017/5217967
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
